Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivos TherapeuticsVVOS -12.93%30 3-Year EPS without NRI Growth Rate is 57.70% as of Jun. 2026, which is 179% above its 10-year median of 20.70. GuruFocus rates VVOS with a GF Score™ of 30/100 and a GF Value™ of $0.90 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Vivos Therapeutics ranks better than 91.64% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 57.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 44.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Vivos Therapeutics was 57.70% per year. The lowest was -21.70% per year. And the median was 20.70% per year.
Vivos Therapeutics (NAS:VVOS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Vivos Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
VVOS vs TRIB, STME, AIDX: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Vivos Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Vivos Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 57.70% mean?
Vivos Therapeutics (VVOS) has a 3-Year EPS without NRI Growth Rate of 57.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vivos Therapeutics and its competitors. This is 179% above median its historical median of 20.70. According to the industry distribution chart, Vivos Therapeutics ranks #55 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 8.4%.
Is Vivos Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Vivos Therapeutics' current 3-Year EPS without NRI Growth Rate of 57.70% is 179% above median its 10-year median of 20.70. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Vivos Therapeutics' value of 57.70% is 616.8% above this industry median. Based on the distribution chart, Vivos Therapeutics ranks #55 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' 3-Year EPS without NRI Growth Rate compare to TRIB and STME?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #55 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places Vivos Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Vivos Therapeutics' value of 57.70% is 616.8% above this benchmark. While the company's 10-year median is 20.70 vs. the industry median of 8.05, Vivos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos Therapeutics's current 3-Year EPS without NRI Growth Rate of 57.70% is 616.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current 3-Year EPS without NRI Growth Rate is 57.70%, which is 179% above median its own 10-year median of 20.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $0.90, compared to a current price of $0.22 — trading 75% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 57.70%, which is 179% above median its 10-year median of 20.70 and 616.8% above the Medical Devices & Instruments industry median of 8.05. Vivos Therapeutics' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current 3-Year EPS without NRI Growth Rate is 57.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.22 is trading 75% below its estimated GF Value™ of $0.90.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
3-Year EPS without NRI Growth Rate: 57.70% (179% above median its 10-year median of 20.70)
GF Value™: $0.90 vs. price of $0.22 (75% below fair value)
Industry Position: 616.8% above the Medical Devices & Instruments median (#55 of 658)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
30GF Score
Get the complete analysis for VVOS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
